The α7 nAChR agonist EVP-6124 has shown positive results in clinical trials for the treatment of conditions such as schizophrenia [21], but trials were discontinued due to side effects from the digestive system; ABT-594 is a less toxic analog of nicotine and has analgesic properties [22]. The gene discussed is CHRNA7; the disease is schizophrenia.